Gemina Laboratories Ltd.
GLABF · OTC
1/31/2025 | 1/31/2024 | 1/31/2023 | 1/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $113 | $93 | $50 | $44 |
| Gross Profit | -$113 | -$93 | -$50 | -$44 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,163 | $2,481 | $4,150 | $2,705 |
| G&A Expenses | $0 | $2,143 | $1,799 | $1,986 |
| SG&A Expenses | $2,636 | $2,605 | $1,799 | $1,986 |
| Sales & Mktg Exp. | $0 | $462 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $3,799 | $5,086 | $5,980 | $4,734 |
| Operating Income | -$3,912 | -$5,086 | -$5,980 | -$4,734 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$162 | -$131 | $281 | $176 |
| Pre-Tax Income | -$4,074 | -$5,217 | -$5,979 | -$4,735 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,074 | -$5,217 | -$5,979 | -$4,735 |
| % Margin | – | – | – | – |
| EPS | -0.055 | -0.072 | -0.099 | -0.099 |
| % Growth | 23.6% | 27.5% | 0.1% | – |
| EPS Diluted | -0.055 | -0.072 | -0.099 | -0.099 |
| Weighted Avg Shares Out | 74,060 | 72,453 | 60,190 | 47,659 |
| Weighted Avg Shares Out Dil | 74,060 | 72,453 | 60,190 | 47,659 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $164 | $19 | $0 | $1 |
| Depreciation & Amortization | $113 | $22 | $50 | $44 |
| EBITDA | -$3,796 | -$5,176 | -$5,930 | -$4,691 |
| % Margin | – | – | – | – |